News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
7,699 Results
Type
Article (1700)
Company Profile (2)
Press Release (5997)
Multimedia
Podcasts (12)
Webinars (1)
Section
Business (2411)
Career Advice (55)
Deals (511)
Drug Delivery (12)
Drug Development (1498)
Employer Resources (15)
FDA (272)
Job Trends (476)
News (4430)
Policy (494)
Tag
Academia (37)
Accelerated approval (1)
Adcomms (1)
Allergies (1)
Alliances (526)
ALS (4)
Alzheimer's disease (35)
Antibody-drug conjugate (ADC) (8)
Approvals (266)
Artificial intelligence (7)
Autoimmune disease (2)
Bankruptcy (2)
Best Places to Work (405)
BIOSECURE Act (1)
Biosimilars (41)
Biotechnology (1)
Brain cancer (1)
Cancer (71)
Cardiovascular disease (5)
Career advice (43)
Career pathing (1)
CAR-T (4)
Cell therapy (16)
Clinical research (1232)
Collaboration (27)
Complete response letters (2)
COVID-19 (51)
C-suite (7)
Cystic fibrosis (3)
Data (55)
Denatured (3)
Depression (7)
Diabetes (1)
Diagnostics (38)
Diversity, equity & inclusion (3)
Drug discovery (10)
Drug pricing (18)
Drug shortages (2)
Duchenne muscular dystrophy (2)
Earnings (870)
Editorial (5)
Employer branding (7)
Employer resources (12)
Events (1111)
Executive appointments (19)
FDA (301)
Funding (16)
Gene editing (2)
Gene therapy (13)
GLP-1 (41)
Government (123)
Guidances (4)
Healthcare (130)
Huntington's disease (3)
Immunology and inflammation (20)
Indications (1)
Infectious disease (54)
Inflammatory bowel disease (14)
Inflation Reduction Act (1)
Interviews (6)
IPO (220)
IRA (6)
Job creations (86)
Job search strategy (41)
Labor market (3)
Layoffs (24)
Legal (132)
Lung cancer (5)
Lymphoma (28)
Management (2)
Manufacturing (6)
MASH (1)
Medical device (37)
Medtech (37)
Mergers & acquisitions (304)
Metabolic disorders (17)
Neurodegenerative disease (14)
Neuropsychiatric disorders (5)
Neuroscience (77)
NextGen: Class of 2025 (106)
Non-profit (39)
Now hiring (29)
Obesity (13)
Opinion (15)
Ovarian cancer (6)
Pain (1)
Parkinson's disease (15)
Partnered (1)
Patents (11)
People (856)
Pharmaceutical (1)
Pharmacy benefit managers (4)
Phase I (369)
Phase II (479)
Phase III (653)
Pipeline (35)
Policy (16)
Postmarket research (24)
Preclinical (88)
Prostate cancer (1)
Psychedelics (2)
Radiopharmaceuticals (1)
Rare diseases (10)
Real estate (52)
Recruiting (8)
Regulatory (316)
Reports (1)
Research institute (43)
Resumes & cover letters (5)
RNA editing (1)
Schizophrenia (22)
Series A (8)
Series B (3)
Special edition (2)
Startups (64)
Supply chain (1)
Tariffs (8)
The Weekly (8)
Vaccines (7)
Venture capitalists (8)
Weight loss (11)
Worklife (1)
Date
Today (1)
Last 7 days (14)
Last 30 days (47)
Last 365 days (617)
2025 (287)
2024 (708)
2023 (610)
2022 (1063)
2021 (915)
2020 (764)
2019 (681)
2018 (550)
2017 (526)
2016 (501)
2015 (553)
2014 (325)
2013 (184)
2012 (29)
2011 (3)
Location
Africa (25)
Arizona (1)
Asia (405)
Australia (46)
California (142)
Canada (21)
China (5)
Colorado (2)
Connecticut (5)
Europe (1256)
Florida (4)
Georgia (4)
Illinois (80)
India (1)
Indiana (7)
Iowa (1)
Japan (6)
Maryland (6)
Massachusetts (80)
Michigan (1)
Minnesota (1)
Missouri (1)
Nebraska (1)
New Hampshire (1)
New Jersey (27)
New York (16)
North Carolina (6)
Northern California (45)
Ohio (3)
Oregon (1)
Pennsylvania (15)
Rhode Island (1)
South America (27)
South Carolina (1)
Southern California (82)
Tennessee (6)
Texas (5)
United States (376)
Virginia (6)
Washington D.C. (3)
Washington State (3)
Wisconsin (2)
7,699 Results for "abbvie".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Lung Cancer
AbbVie’s ADC Nabs Accelerated Approval for Lung Cancer
AbbVie’s Emrelis is the first non-small cell lung cancer therapy approved for patients with high c-Met expression levels who have received prior lines of treatment.
May 15, 2025
·
2 min read
·
Tristan Manalac
Drug discovery
AbbVie Dives Further Into siRNA With $335M Upfront in ADARx Deal
The ADARx Pharmaceuticals partnership, which could be worth “several billion dollars” in the end, adds to AbbVie’s existing work in the space after the $1.4 billion acquisition of Aliada Therapeutics in October 2024.
May 14, 2025
·
2 min read
·
Annalee Armstrong
Earnings
AbbVie Criticizes Trump’s Drug Pricing Proposal, Deflects Tariff Concerns
While AbbVie handily beat expectations this quarter, the company faces declining Humira sales and a challenged aesthetics business, plus the same macro headwinds blowing against the entire industry.
April 25, 2025
·
3 min read
·
Annalee Armstrong
Earnings
AbbVie’s Marketing Misstep Further Erodes 2024 Aesthetics Sales
AbbVie launched a revamped version of its Allē loyalty program, which ultimately was not adopted by providers. The marketing misstep comes as the company’s aesthetics franchise faces broader pressures.
February 3, 2025
·
4 min read
·
Annalee Armstrong
Legal
AbbVie Lawsuit Alleges That Partner Genmab “Misappropriated” Trade Secrets
AbbVie claims that Genmab turned a blind eye to trade secret theft allegedly used to support the development of ProfoundBio’s investigational antibody-drug conjugates. Genmab acquired ProfoundBio in May 2024.
March 24, 2025
·
2 min read
·
Tristan Manalac
Layoffs
AbbVie’s Allergan Cuts Over 200 Staff After Botched Marketing Campaign
The layoffs will take effect on July 22 and particularly target those working in sales, data engineering and product management.
May 28, 2025
·
2 min read
·
Tristan Manalac
Press Releases
AbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award™ Contest to Support Their Professional Goals
June 3, 2025
·
5 min read
Neuropsychiatric disorders
AbbVie Absorbs $3.5B Cost of Schizophrenia Flop
Emraclidine was the centerpiece of AbbVie’s $8.7 billion acquisition of Cerevel in December 2023 but failed two mid-stage trials. Tavapadon, meanwhile, has been a more rewarding asset for the pharma, clearing three Phase III Parkinson’s studies in 2024.
January 13, 2025
·
2 min read
·
Tristan Manalac
Obesity
Obesity Late-Comer AbbVie Inks up to $2.2B Amylin Deal With Gubra
AbbVie is joining the amylin arena, though the pharma is still far behind leaders Novo Nordisk and Eli Lilly.
March 3, 2025
·
2 min read
·
Tristan Manalac
Press Releases
AbbVie Partners with Chicago Cubs on “Striking Out Cancer”
May 30, 2025
·
5 min read
1 of 770
Next
